Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals’ perceptions, knowledge, and educational needsThe Pharmacogenomics JournalIF02026-01-200OAAI
ACKR1 genetic testing should be offered before starting clozapine treatmentACKR1基因检测应在开始氯氮平治疗前进行Nature Mental HealthIF8.72026-01-011PRE
Effect of polygenic scores on the relationship between psychosis and cognition多基因评分对精神病与认知关系的影响Translational PsychiatryIF6.22025-11-210OAAI
Patient and clinician perspectives on pharmacogenetic testing for antipsychotics患者和临床医生对精神药物药物基因组学检测的看法Frontiers in PharmacologyIF4.82025-10-090OAAI
ADAPTIVE-SAMPLING NANOPORE SEQUENCING IN THE G-PAT STUDY: A MULTIOMICS APPROACH FOR THE CHARACTERISATION OF RARE PHARMACOGENE VARIANTS IN PSYCHOSISEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72024-10-010PRE
COST-EFFECTIVENESS ANALYSIS OF PHARMACOGENETIC TESTING TO GUIDE TREATMENT IN SCHIZOPHRENIAEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72024-10-010PRE
IMPLEMENTING ACKR1 VARIANT TESTING IN ENG-LAND FOR CLOZAPINE THERAPYEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72024-10-010PRE
Is auditory processing measured by the N100 an endophenotype for psychosis? A family study and a meta-analysisPSYCHOLOGICAL MEDICINEIF5.52023-11-244OA
PHARMACOGENETIC TESTING TO GUIDE ANTIPSYCHOTIC TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSISEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72023-10-010PRE
POLYGENIC SCORES AND THE RELATIONSHIP BETWEEN COGNITION AND PSYCHOSISEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72023-10-010PRE
ASSESSMENT OF PHARMACOGENETIC ANALYSIS TECHNOLOGIES APPLIED IN THE G-PAT STUDY: MULTI-MODAL CHARACTERIZATION OF KEY PHARMACOGENES IN THE CONTEXT OF PSYCHOSISEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72023-10-010PRE
CARDIOMETABOLIC ABNORMALITIES IN SCHIZOPHRE-NIA. CAUSE OR CONSEQUENCE?EUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72022-10-010PRE